S&P 500   3,336.74 (-1.08%)
DOW   28,932.36 (-0.98%)
QQQ   231.31 (-1.48%)
AAPL   315.71 (-1.43%)
FB   210.39 (-1.96%)
MSFT   180.26 (-2.26%)
GOOGL   1,498.01 (-1.25%)
AMZN   2,115.40 (-1.75%)
CGC   22.00 (-1.39%)
NVDA   297.23 (-3.72%)
BABA   213.26 (-2.19%)
MU   57.31 (-2.86%)
GE   12.30 (-1.84%)
AMD   55.05 (-3.88%)
T   38.53 (-0.23%)
ACB   1.65 (-1.78%)
F   7.93 (-1.25%)
NFLX   381.64 (-1.13%)
BAC   34.24 (-1.75%)
DIS   139.22 (-0.82%)
S&P 500   3,336.74 (-1.08%)
DOW   28,932.36 (-0.98%)
QQQ   231.31 (-1.48%)
AAPL   315.71 (-1.43%)
FB   210.39 (-1.96%)
MSFT   180.26 (-2.26%)
GOOGL   1,498.01 (-1.25%)
AMZN   2,115.40 (-1.75%)
CGC   22.00 (-1.39%)
NVDA   297.23 (-3.72%)
BABA   213.26 (-2.19%)
MU   57.31 (-2.86%)
GE   12.30 (-1.84%)
AMD   55.05 (-3.88%)
T   38.53 (-0.23%)
ACB   1.65 (-1.78%)
F   7.93 (-1.25%)
NFLX   381.64 (-1.13%)
BAC   34.24 (-1.75%)
DIS   139.22 (-0.82%)
S&P 500   3,336.74 (-1.08%)
DOW   28,932.36 (-0.98%)
QQQ   231.31 (-1.48%)
AAPL   315.71 (-1.43%)
FB   210.39 (-1.96%)
MSFT   180.26 (-2.26%)
GOOGL   1,498.01 (-1.25%)
AMZN   2,115.40 (-1.75%)
CGC   22.00 (-1.39%)
NVDA   297.23 (-3.72%)
BABA   213.26 (-2.19%)
MU   57.31 (-2.86%)
GE   12.30 (-1.84%)
AMD   55.05 (-3.88%)
T   38.53 (-0.23%)
ACB   1.65 (-1.78%)
F   7.93 (-1.25%)
NFLX   381.64 (-1.13%)
BAC   34.24 (-1.75%)
DIS   139.22 (-0.82%)
S&P 500   3,336.74 (-1.08%)
DOW   28,932.36 (-0.98%)
QQQ   231.31 (-1.48%)
AAPL   315.71 (-1.43%)
FB   210.39 (-1.96%)
MSFT   180.26 (-2.26%)
GOOGL   1,498.01 (-1.25%)
AMZN   2,115.40 (-1.75%)
CGC   22.00 (-1.39%)
NVDA   297.23 (-3.72%)
BABA   213.26 (-2.19%)
MU   57.31 (-2.86%)
GE   12.30 (-1.84%)
AMD   55.05 (-3.88%)
T   38.53 (-0.23%)
ACB   1.65 (-1.78%)
F   7.93 (-1.25%)
NFLX   381.64 (-1.13%)
BAC   34.24 (-1.75%)
DIS   139.22 (-0.82%)
Log in

NASDAQ:AVEO - AVEO Pharmaceuticals Stock Price, Forecast & News

$5.19
-0.06 (-1.14 %)
(As of 02/21/2020 10:49 AM ET)
Today's Range
$5.03
Now: $5.19
$5.32
50-Day Range
$0.51
MA: $0.68
$5.25
52-Week Range
$4.65
Now: $5.19
$18.50
Volume88,542 shs
Average Volume1.80 million shs
Market Capitalization$834.56 million
P/E RatioN/A
Dividend YieldN/A
Beta0.73
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AVEO
CUSIP05358810
Phone617-588-1960

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.41 million
Book Value($0.22) per share

Profitability

Net Income$-5,330,000.00

Miscellaneous

Employees17
Market Cap$834.56 million
Next Earnings Date3/12/2020 (Estimated)
OptionableOptionable

Receive AVEO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVEO and its competitors with MarketBeat's FREE daily newsletter.


AVEO Pharmaceuticals (NASDAQ:AVEO) Frequently Asked Questions

What is AVEO Pharmaceuticals' stock symbol?

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

When did AVEO Pharmaceuticals' stock split? How did AVEO Pharmaceuticals' stock split work?

Shares of AVEO Pharmaceuticals reverse split before market open on Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 19th 2020. An investor that had 100 shares of AVEO Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were AVEO Pharmaceuticals' earnings last quarter?

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced its earnings results on Tuesday, November, 12th. The biopharmaceutical company reported $1.02 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.07 by $0.95. The biopharmaceutical company had revenue of $25.72 million for the quarter. AVEO Pharmaceuticals had a net margin of 120.85% and a negative return on equity of 561.43%. View AVEO Pharmaceuticals' Earnings History.

When is AVEO Pharmaceuticals' next earnings date?

AVEO Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for AVEO Pharmaceuticals.

What price target have analysts set for AVEO?

3 equities research analysts have issued twelve-month target prices for AVEO Pharmaceuticals' shares. Their forecasts range from $17.50 to $20.00. On average, they anticipate AVEO Pharmaceuticals' share price to reach $18.75 in the next twelve months. This suggests a possible upside of 260.6% from the stock's current price. View Analyst Price Targets for AVEO Pharmaceuticals.

What is the consensus analysts' recommendation for AVEO Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AVEO Pharmaceuticals.

What are Wall Street analysts saying about AVEO Pharmaceuticals stock?

Here are some recent quotes from research analysts about AVEO Pharmaceuticals stock:
  • 1. HC Wainwright analysts commented, "We raise our rating on AVEO to and increase our 12-month price target to $1.75 per share. We derive our price target based on a risk-adjusted NPV analysis of projected tivozanib and ficlatuzumab revenues through 2030, assuming a 12.0% discount rate and a 0% terminal growth rate. We derive an rNPV of $393M for the products and add in pro forma net cash and cash equivalents of $65.2M to arrive at a 12-month price target of $1.75 per share. (1) clinical; (2) commercial; (3) financial; (4) partnership; and (5) intellectual property." (9/11/2019)
  • 2. According to Zacks Investment Research, "AVEO missed on both earnings and revenues in the first quarter of 2019. The company got a huge boost from the approval for Fotivda in Europe regarding the first-line treatment of advanced renal cell carcinoma (RCC).However, AVEO faced a major setback when it had to delay its submission of a new drug application (NDA) for Fotivda in the United States. The company intended to submit the NDA in the first half of 2019 but now interim data will be available during the fourth quarter of 2019, subject to mature OS results. Although, the target market is lucrative, dependence on partners for pipeline development and funds accumulation is a concern. Failure to receive regulatory approvals or the termination of a deal would hamper AVEO’s future prospects. AVEO receives royalties from Fotivda sales in certain European countries. This is a key revenue driver. Shares of the company have underperformed the industry so far this year." (5/15/2019)

Has AVEO Pharmaceuticals been receiving favorable news coverage?

Headlines about AVEO stock have been trending negative this week, InfoTrie reports. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AVEO Pharmaceuticals earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for AVEO Pharmaceuticals.

Are investors shorting AVEO Pharmaceuticals?

AVEO Pharmaceuticals saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 16,400,000 shares, a decrease of 5.0% from the January 15th total of 17,270,000 shares. Based on an average daily trading volume, of 1,900,000 shares, the days-to-cover ratio is currently 8.6 days. Approximately 12.2% of the shares of the stock are short sold. View AVEO Pharmaceuticals' Current Options Chain.

Who are some of AVEO Pharmaceuticals' key competitors?

What other stocks do shareholders of AVEO Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Exelixis (EXEL), Advanced Micro Devices (AMD), Synergy Pharmaceuticals (SGYP), Micron Technology (MU), Novavax (NVAX), Amarin (AMRN), Alibaba Group (BABA), Canopy Growth (CGC), Bellicum Pharmaceuticals (BLCM) and Opko Health (OPK).

Who are AVEO Pharmaceuticals' key executives?

AVEO Pharmaceuticals' management team includes the folowing people:
  • Mr. Michael P. Bailey, CEO, Pres & Director (Age 54)
  • Ms. Karuna Rubin, Sr. VP & Gen. Counsel (Age 42)
  • Dr. Michael N. Needle, Chief Medical Officer (Age 59)
  • Dr. Nikhil Mehta Ph.D., Sr. VP of Regulatory & Quality Assurance (Age 60)
  • Dr. Emile Farhan Ph.D., VP of Technical Operations

Who are AVEO Pharmaceuticals' major shareholders?

AVEO Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Jacobs Levy Equity Management Inc. (0.90%), Geode Capital Management LLC (0.61%), Marshall Wace LLP (0.18%), Virtu Financial LLC (0.14%) and Goldman Sachs Group Inc. (0.03%). Company insiders that own AVEO Pharmaceuticals stock include Anthony B Evnin, Equity Opportunities Fu Growth, Equity Opportunities Iv Growth, Michael P Bailey, Peter J Barris, Peter W Sonsini and Ravi Viswanathan. View Institutional Ownership Trends for AVEO Pharmaceuticals.

Which institutional investors are selling AVEO Pharmaceuticals stock?

AVEO stock was sold by a variety of institutional investors in the last quarter, including Geode Capital Management LLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for AVEO Pharmaceuticals.

Which institutional investors are buying AVEO Pharmaceuticals stock?

AVEO stock was purchased by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Marshall Wace LLP and Virtu Financial LLC. Company insiders that have bought AVEO Pharmaceuticals stock in the last two years include Anthony B Evnin, Equity Opportunities Fu Growth, Equity Opportunities Iv Growth, Michael P Bailey, Peter J Barris, Peter W Sonsini and Ravi Viswanathan. View Insider Buying and Selling for AVEO Pharmaceuticals.

How do I buy shares of AVEO Pharmaceuticals?

Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AVEO Pharmaceuticals' stock price today?

One share of AVEO stock can currently be purchased for approximately $5.20.

How big of a company is AVEO Pharmaceuticals?

AVEO Pharmaceuticals has a market capitalization of $836.26 million and generates $5.41 million in revenue each year. The biopharmaceutical company earns $-5,330,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. AVEO Pharmaceuticals employs 17 workers across the globe.View Additional Information About AVEO Pharmaceuticals.

What is AVEO Pharmaceuticals' official website?

The official website for AVEO Pharmaceuticals is http://www.aveooncology.com/.

How can I contact AVEO Pharmaceuticals?

AVEO Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-588-1960 or via email at [email protected]


MarketBeat Community Rating for AVEO Pharmaceuticals (NASDAQ AVEO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  366 (Vote Outperform)
Underperform Votes:  349 (Vote Underperform)
Total Votes:  715
MarketBeat's community ratings are surveys of what our community members think about AVEO Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVEO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Featured Article: What is a stock split?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel